bFGF

PreclinicalSmall molecule

SShanghai Dermatology Hospital

bFGF is one of 32 small molecule programs targeting Growth. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthActive, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

Genotropin

EMD Serono

Preclinical

35 2

Aricept

Eisai

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Lenvima

Eisai

Preclinical

1 6

Herceptin

OOrganon and Co

Preclinical

4 7

Somavaratan

Glucophage

2 9

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Glucagon

XXeris Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Growth1 trial

The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin

Recruiting·SShanghai Dermatology Hospital·N/A·NCT06516939·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for bFGF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bFGF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bFGF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Dermatology Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Dermatology Hospital

bFGF

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Growth1 trial

References

Drug Info

Quick Facts

Related News